WeConnectPatients.com · Joint & Immune Health

It’s not just psoriasis. And it’s not just arthritis. It’s both — and you deserve a plan for the whole picture.

Psoriatic arthritis is a chronic inflammatory condition that attacks your joints and your skin. It’s driven by your immune system — and the right treatment can change how you live with it.

Americans

Estimated to be living with psoriatic arthritis — with many more likely undiagnosed

Of Psoriasis Patients

Up to 30% of people with psoriasis develop PsA

Typical Diagnostic Delay

Studies suggest many people with PsA wait years before receiving an accurate diagnosis

Erosive Disease Risk

Joint damage can develop in those with undertreated or uncontrolled PsA — underscoring why early diagnosis matters

Your immune system is attacking your joints. That’s the core of what’s happening.

Psoriatic arthritis isn’t just soreness or stiffness. It’s your immune system going after your joints, tendons, and skin all at once. The aching you feel in the morning, the swelling that won’t quit — that’s inflammation with a cause. And that cause has a name.

An estimated 1 to 3 million Americans are living with PsA right now, though many remain undiagnosed. Most of them had psoriasis first — in roughly 70–80% of cases, the skin condition shows up before the joint condition. But not always. Some people develop joint symptoms first, or both at the same time.

PsA is widely variable. Some people have a handful of affected joints. Others have dozens. It can hit your fingers, toes, knees, spine, or where tendons attach to bone. That variability is part of what makes it so hard to diagnose.

Here’s the part that doesn’t get talked about enough: more than half of people with PsA report significant fatigue. It’s linked to higher rates of cardiovascular disease, diabetes, and depression. And published research suggests the average person waits 3 to 7 years for the right diagnosis.

The damage PsA causes isn’t cosmetic. Without adequate treatment, an estimated 40–50% of people develop erosive joint disease — permanent changes that can’t be reversed (a population-level estimate; individual outcomes vary with early intervention). Getting the right diagnosis early isn’t optional. It’s urgent.

What drives psoriatic arthritis

PsA is an immune-mediated condition. Your body’s defense system turns on your own joints and connective tissue. A few factors determine who develops it.

Your immune system

Certain immune signaling proteins — called TNF (tumor necrosis factor), IL-17, and IL-23 — drive the chronic inflammation in your joints, tendons, and skin. These are the same pathways targeted by many of the most effective PsA treatments. It’s not wear and tear. It’s your immune system actively causing damage.

Your psoriasis history

Up to 30% of people with psoriasis eventually develop PsA. Nail involvement — pitting, ridging, or lifting — is one of the strongest predictors. If your nails are changing, tell your doctor.

Genetics

PsA runs in families. Specific immune system genes increase your risk. Having a first-degree relative with PsA or psoriasis raises your odds significantly. But genes alone don’t determine your fate.

Physical stress and injury

Joint trauma, repetitive strain, or infections can trigger the onset of PsA in people who are genetically predisposed. This is sometimes called the Koebner phenomenon — a pattern in which physical stress or injury triggers disease activity in people who are already susceptible.

Diagnostic delay hurts everyone — but not equally

African American and Hispanic patients experience 1–2 years longer diagnostic delays on average. On darker skin, psoriasis may present differently, and PsA symptoms may be attributed to other conditions. If you feel dismissed, seek a rheumatologist who specializes in PsA.

How psoriatic arthritis is diagnosed

There’s no single test for PsA. Diagnosis depends on recognizing a pattern — and that takes a provider who knows what to look for.

Clinical exam

A rheumatologist — a doctor who specializes in joint and immune conditions — will check for swollen joints, tender points, reduced range of motion, and enthesitis (pain where tendons attach to bone). Dactylitis (a condition where an entire finger or toe swells to a sausage-like shape) is a hallmark sign of PsA. If you don’t have immediate access to a rheumatologist, ask your primary care provider to start the referral process.

Your skin and nail history

Since psoriasis precedes PsA in most cases, your skin history matters enormously. Nail changes are a strong signal. Your rheumatologist should coordinate with your dermatologist — or be checking your skin themselves.

Imaging

X-rays may show joint erosion in advanced cases. MRI and ultrasound can catch inflammation earlier, including enthesitis and synovitis that aren’t visible on standard X-rays. Early imaging can change your treatment trajectory.

Lab work

Blood tests help rule out rheumatoid arthritis and gout. PsA is typically seronegative — meaning rheumatoid factor is negative. Elevated inflammatory markers support the diagnosis but aren’t always present.

The whole-person picture

A good rheumatologist doesn’t just count joints. They ask about fatigue, mood, skin flares, eye inflammation, sleep quality, and cardiovascular risk. PsA is systemic. The diagnosis should reflect that.

Treatment has come a long way

The goal isn’t managing symptoms. It’s stopping joint damage, clearing skin, reducing fatigue, and getting your life back.

First Line

Conventional DMARDs (Disease-Modifying Medications)

Methotrexate is often the first systemic treatment tried. DMARDs (disease-modifying antirheumatic drugs) work to slow the disease process, not just relieve symptoms. Methotrexate works for an estimated 40–50% of people, particularly for skin and peripheral joints. It’s well-studied and affordable. But for many, it’s not enough on its own.

Biologics

TNF, IL-17 & IL-23 Inhibitors

Biologic therapies target the specific immune signaling proteins driving PsA. In clinical studies, TNF inhibitors achieve meaningful improvement in roughly 50–70% of patients. IL-17 and IL-23 inhibitors often show similar or slightly higher response rates. These response rates measure significant symptom improvement; full remission is achieved by fewer people (see Fair-Balance Note below). These medications can treat your joints and skin simultaneously.

Targeted Oral

JAK Inhibitors and TYK2 Inhibitors

These are two distinct classes of oral medications that work inside cells to block different inflammatory signaling pathways. They work differently from conventional DMARDs like methotrexate — they block specific inflammatory signals rather than broadly suppressing the immune system. JAK inhibitors are established in PsA treatment; TYK2 inhibitors represent a newer approach being studied in PsA. Both offer alternatives to injections for people who prefer oral therapy.

What’s Next

The Pipeline Is Active

As of early 2026, researchers are testing next-generation therapies with new mechanisms, broader efficacy, and greater convenience. Clinical trials are where these options become available first — often with specialized monitoring and no cost for the medication.

All treatments carry potential side effects and don’t work for everyone. Only 15–20% of people with PsA achieve full clinical remission with current therapies. Talk to your rheumatologist about which risks, benefits, and goals apply to you.

“I spent years thinking the pain was just part of having psoriasis. Getting the right diagnosis changed everything.”

Reflects common patient experiences

If cost is a barrier, ask your rheumatologist or pharmacist about patient assistance programs — most biologic manufacturers offer them, and organizations like the National Psoriasis Foundation can help you navigate your options. Some clinical trials also provide the study medication at no cost.

Answers to common questions

Living with PsA raises real, practical questions. Here are honest answers to some of the most common ones.

How is PsA different from regular arthritis?

PsA is driven by your immune system, not wear and tear. It attacks joints, tendons, and skin simultaneously. It can also cause fatigue, nail changes, and eye inflammation. Understanding this distinction matters because the treatments are fundamentally different.

Does PsA cause permanent damage?

It can. Without adequate treatment, an estimated 40–50% of people develop erosive joint disease (a population-level estimate; individual outcomes vary). That’s why early, aggressive treatment matters — once joint damage happens, it can’t be reversed. The goal is to get inflammation under control before damage starts.

Why am I so tired all the time?

More than half of people with PsA report significant fatigue — even when their joints feel okay. It’s not laziness. It’s your immune system working overtime. PsA is also linked to higher rates of depression and anxiety, and chronic pain can affect concentration and mental clarity. Tell your doctor about all of it — fatigue, mood changes, and brain fog are treatable and deserve attention, not just joint symptoms.

Can PsA affect more than just my joints?

Yes. PsA is a systemic condition. It can affect your skin, nails, eyes, tendons, and spine. It’s also linked to higher risks of cardiovascular disease, diabetes, and depression. A good rheumatologist monitors the whole picture.

How long does it take to get diagnosed?

Too long for most people. Published research suggests the average delay is 3 to 7 years. PsA is often misdiagnosed as osteoarthritis or rheumatoid arthritis. If you have psoriasis and joint pain, bring up PsA specifically with your doctor.

Does PsA affect different communities differently?

Yes. African American and Hispanic patients tend to experience longer diagnostic delays — sometimes 1–2 years more. If you feel dismissed or undertreated, seek a rheumatologist who understands PsA across diverse populations.

What about my psoriasis?

PsA and psoriasis are connected — same immune pathways, often same treatments. Many biologics can treat both simultaneously. If you’re seeing a dermatologist for your skin and a rheumatologist for your joints, make sure they’re coordinating.

Are there communities I can connect with?

The National Psoriasis Foundation and Arthritis Foundation both offer PsA-specific resources. Online communities, support groups, and social media connections can help you learn from others living with the same condition.

Research & Progress

The science is moving fast

The science behind PsA treatment has advanced significantly over the past decade. Researchers now understand the specific immune pathways involved, and that understanding is producing treatments that would have seemed unlikely just a few years ago.

What’s in the pipeline: next-generation biologics with broader efficacy, new oral therapies that block inflammatory signaling more precisely, and combination approaches that target joints and skin together. The goal is moving beyond partial response toward real remission.

Clinical trials are how these treatments get tested and made available. Participating gives you access to specialized care teams and emerging therapies while contributing to progress for everyone with PsA. Participation is always voluntary. Your care team will explain how a trial fits alongside your current treatment plan.

Your joints and your skin deserve better. Not just management — real progress.

PsA research is advancing fast. Whether you’re newly diagnosed or have been managing it for years, there may be treatment options you haven’t explored.

Not sure where to start?

Walking into a rheumatology appointment with the right questions changes everything. We put together a quick guide.

This content is for educational purposes only and isn’t a substitute for medical advice. Talk to your healthcare provider before making decisions about your care. Information about clinical trials is for general awareness, not an endorsement of any specific study.

Sources: National Psoriasis Foundation, ACR, NIH/NIAMS, Mayo Clinic, Cleveland Clinic, N Engl J Med, Nat Rev Rheumatol, Semin Arthritis Rheum, peer-reviewed literature (2017–2024), ClinicalTrials.gov.

WeConnect is a Takeda initiative connecting people to clinical trial opportunities. Visit WeConnectPatients.com.